Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards BreakevenGlobeNewsWire • 08/03/23
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023GlobeNewsWire • 08/01/23
Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow BiopsyGlobeNewsWire • 06/14/23
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® TechnologyGlobeNewsWire • 06/13/23
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewsWire • 06/08/23
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency ProjectsGlobeNewsWire • 06/07/23
Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® TechnologyGlobeNewsWire • 05/22/23
Precipio Adds Substantial Pathology Customer to its Diagnostic Services DivisionGlobeNewsWire • 05/04/23
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) CombinedGlobeNewsWire • 04/19/23
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customersGlobeNewsWire • 03/07/23